HC Wainwright Issues Optimistic Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research report issued on Wednesday, January 22nd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.78) for the quarter, up from their prior forecast of ($0.81). HC Wainwright has a “Buy” rating and a $39.00 price objective on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS and FY2025 earnings at ($3.41) EPS.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $27.25 on Friday. ArriVent BioPharma has a 12 month low of $14.35 and a 12 month high of $36.37. The stock’s fifty day moving average price is $26.99 and its 200-day moving average price is $25.97.

Hedge Funds Weigh In On ArriVent BioPharma

Institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of ArriVent BioPharma during the fourth quarter valued at $190,000. The Manufacturers Life Insurance Company bought a new stake in ArriVent BioPharma during the third quarter valued at about $240,000. SG Americas Securities LLC bought a new stake in ArriVent BioPharma during the third quarter valued at about $280,000. JPMorgan Chase & Co. boosted its position in ArriVent BioPharma by 183.2% during the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock valued at $292,000 after purchasing an additional 8,050 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in ArriVent BioPharma by 30.1% during the second quarter. Rhumbline Advisers now owns 12,707 shares of the company’s stock valued at $236,000 after purchasing an additional 2,942 shares in the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.